Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 5/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 4/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25367766 | 0.97 | TNF (0.41) | TNFDYRK1AAKR1C3JAK3PTK2 | |
| SCHEMBL25365655 | 0.85 | GPR119 (0.43) | AKR1C3JAK3TLR9JAK2GPR119 | |
| SCHEMBL25365448 | 0.83 | HRH3 (0.43) | TNFDYRK1AJAK3MTORPIK3CA | |
| SCHEMBL25365024 | 0.82 | GPR119 (0.45) | AKR1C3JAK3MTORPIK3CAJAK2 | |
| SCHEMBL25363492 | 0.73 | TLR9 (0.43) | AKR1C3JAK3PTK2TLR9JAK2 | |
| SCHEMBL25366146 | 0.73 | HRH3 (0.47) | TNFAKR1C3JAK3PTK2JAK2 | |
| SCHEMBL30557377 | 0.73 | HRH3 (0.47) | TNFAKR1C3JAK3PTK2JAK2 | |
| SCHEMBL25368100 | 0.70 | HRH3 (0.37) | TNFJAK3PTK2MTORPIK3CA | |
| SCHEMBL30557460 | 0.70 | HRH3 (0.37) | TNFJAK3PTK2MTORPIK3CA | |
| SCHEMBL25364691 | 0.69 | CYP2D6 (0.40) | JAK3PTK2MTORPIK3CAJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177363-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4479135-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Bristol-Myers Squibb Company (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023159154-A9 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2023159154-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177363-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | TNF 1741/4885DYRK1A 3283/4885AKR1C3 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.